[go: up one dir, main page]

EP2149603A1 - Variantes du facteur IX dotées d'activité de coagulation en l'absence de leur cofacteur et leur utilisation pour le traitement de troubles du sang - Google Patents

Variantes du facteur IX dotées d'activité de coagulation en l'absence de leur cofacteur et leur utilisation pour le traitement de troubles du sang Download PDF

Info

Publication number
EP2149603A1
EP2149603A1 EP08013561A EP08013561A EP2149603A1 EP 2149603 A1 EP2149603 A1 EP 2149603A1 EP 08013561 A EP08013561 A EP 08013561A EP 08013561 A EP08013561 A EP 08013561A EP 2149603 A1 EP2149603 A1 EP 2149603A1
Authority
EP
European Patent Office
Prior art keywords
factor
variant
amino acid
viii
acid substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08013561A
Other languages
German (de)
English (en)
Inventor
Erhard Seifried
Jörg Schüttrumpf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DRK Blutspendedienst Baden Wuerttermberg Hessen gGmbH
Original Assignee
DRK Blutspendedienst Baden Wuerttermberg Hessen gGmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DRK Blutspendedienst Baden Wuerttermberg Hessen gGmbH filed Critical DRK Blutspendedienst Baden Wuerttermberg Hessen gGmbH
Priority to EP08013561A priority Critical patent/EP2149603A1/fr
Priority to KR1020177022245A priority patent/KR101947424B1/ko
Priority to ES11005215.6T priority patent/ES2441167T3/es
Priority to KR1020117001765A priority patent/KR101768896B1/ko
Priority to ES17164245T priority patent/ES2753638T3/es
Priority to EP19191719.4A priority patent/EP3623470A3/fr
Priority to CA3033578A priority patent/CA3033578C/fr
Priority to PCT/EP2009/005465 priority patent/WO2010012451A1/fr
Priority to EP17164245.7A priority patent/EP3241899B1/fr
Priority to EP11005215.6A priority patent/EP2390323B1/fr
Priority to JP2011520375A priority patent/JP6029826B2/ja
Priority to AU2009275391A priority patent/AU2009275391B2/en
Priority to US13/001,187 priority patent/US10125357B2/en
Priority to EP09777493A priority patent/EP2318526A1/fr
Priority to CN2009801296698A priority patent/CN102112608B/zh
Priority to ES14165396.4T priority patent/ES2628688T3/es
Priority to EP14165396.4A priority patent/EP2767587B1/fr
Priority to CA2729501A priority patent/CA2729501C/fr
Publication of EP2149603A1 publication Critical patent/EP2149603A1/fr
Priority to US16/148,819 priority patent/US10883097B2/en
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/9645—Factor IX (3.4.21.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation

Definitions

  • the present invention relates to variants of a vitamin K-dependent serine protease of the coagulation cascade, preferably variants of factor IX (F.IX), wherein the variant is characterized in that it has clotting activity in absence of its cofactor.
  • the present invention furthermore relates to the use of these variants for the treatment and/or prophylaxis of bleeding disorders, in particular hemophilia A and/or hemophilia B or hemophilia caused or complicated by inhibitory antibodies to F.VIII.
  • the present invention also relates to further variants of factor IX (F.IX) which have desired properties and can, thus be tailored for respective specific therapeutic applications.
  • the blood coagulation factor IX plays a central role in the coagulation cascade.
  • F.IX is a trypsin-like vitamin K-dependent serine protease that circulates in the plasma as a single chain inactive zymogen (DiScipio et al., 1977; Davie et al., 1991).
  • Factor IX is activated by either factor XIa or by factor VIIa-tissue factor in a Ca 2+ dependent manner.
  • the activation requires cleavage of two peptide bonds by either the activated factor VII (F.VIIa)-tissue factor complex or activated factor XI (F.XIa) (Fujikawa et al ., 1974; Lindquist et al ., 1978) to remove a 35-residue activation peptide.
  • F.VIIa activated factor VII
  • F.XIa activated factor XI
  • F.IX is a multi-domain protein.
  • GLA N-terminal ⁇ -carboxy glutamic acid
  • AP activation peptide
  • C-terminal serine protease domain with a trypsin-like active site (DiScipio et al ., 1978).
  • This domain structure defines the serine protease family of clotting factors (Furie and Furie, 1988), including also factor II (F.II), factor VII (F.VII), factor X (F.X), factor XI (F.XI), factor XII (F.XII), and protein C (PC).
  • F.IXa has unique proteolytic properties. Complex formation of F.IXa with F.VIIIa on a phospholipid surface increases reactivity against the natural substrate F.X 10 6 -fold (Duffy and Lollar, 1992), while virtually no cleavage of peptides with corresponding F.X sequences was observed (McRae et al ., 1981).
  • Activated factor IX then activates factor X (F.X) in a reaction that is dependent on the presence of calcium ions, a membrane surface (phospholipid), and a nonenzymatic protein cofactor, activated factor VIII (F.VIIIa) (Davie et al ., 1991).
  • F.IXa displays only very little proteolytic activity against natural or synthetic substrates in the absence of its cofactor F.VIIIa. Binding of F.VIIIa results in a 10 6 -fold increase in proteolytic activity for F.X, whereas the activity with peptidic substrates remains less affected (Duffy and Lollar, 1992; McRae et al ., 1981).
  • F.IXa modulation substrate-dependent activity of F.IXa modulation is similarly observed for the related coagulation enzymes activated PC (co-factor Protein S), F.Xa (co-factor Factor Va), F.VIIa (cofactor tissue factor), and FIIa (co-factor thrombomodulin), which in the presence of their cofactors, achieve a significant activity or specificity change with their natural substrates.
  • PC co-factor Protein S
  • F.Xa co-factor Factor Va
  • F.VIIa cofactor tissue factor
  • FIIa co-factor thrombomodulin
  • coagulation factors IXa F.IXa
  • Xa Xa
  • Hopfner et al . investigated variants of truncated F.IXa (rf9a) and F.Xa (rf10a) in E. coli to identify determinants of the difference in the amidolytic activity of F.IXa which is 10 4 -fold lower than that of F.Xa.
  • F.IXa is characterized by its very low amidolytic activity that is not improved in the presence of cofactor, factor VIIIa (F.VIIIa), distinguishing F.IXa from all other coagulation factors.
  • Activation of the F.IXa-F.VIIIa complex requires its macromolecular substrate, factor X (F.X).
  • F.X factor X
  • the 99-loop positioned near the active site partly accounts for the poor activity of F.IXa because it adopts a conformation that interferes with canonical substrate binding in the subsites S2-S4.
  • Sichler et al. (2003) disclose that residues Lys-98 and Tyr-99 (chymotrypsin numbering) are critically linked to the amidolytic properties of F.IXa.
  • Hemophilia is the name of a family of hereditary genetic disorders that impair the body's ability to control blood clotting, or coagulation.
  • Haemophilia A the most common form, is caused by a mutation of the factor VIII (F.VIII) gene, leading to a deficiency in F.VIII.
  • F.VIII factor VIII
  • the inheritance is X-linked recessive; hence, males are affected while females are carriers or very rarely display a mild phenotype. 1 in 5,000 males are affected.
  • Hemophilia B also known as factor IX (F.IX) deficiency, is the second most common type of hemophilia, but hemophilia B is far less common than hemophilia A.
  • haemophilia Although there is no cure for haemophilia, it can be controlled with regular infusions of the deficient clotting factor, i.e. F.VIII in haemophilia A or F.IX in haemophilia B.
  • prophylaxis involves the infusion of coagulation factor on a regular schedule in order to keep clotting levels sufficiently high to prevent spontaneous bleeding episodes.
  • On-demand treatment involves treating bleeding episodes once they arise.
  • haemophiliacs develop antibodies (inhibitors) against the replacement factors given to them, so the amount of the factor has to be increased or non-human replacement products must be given, such as porcine F.VIII or modified variants thereof, see e.g. WO 01/68109 A1 (Emory University).
  • risks of using an already activated protease, like factor VIIa, over prolonged time intervals might carry risks, including thrombotic risks, risks through constant activation of the vascular endothelium and vessel damage, risk of pro-coagulant signalling which could promote tumor growth or metastasis, etc.
  • WO 02/40544 A2 discloses mutant human factor IX comprising mutations in the heparin binding domain, which decrease the affinity of the mutant human F.IX for heparin compared to wild type F.IX, and their use in the therapeutic intervention of hemophilia B.
  • Hemophilia is ideal for a gene therapeutic approach since the required coagulation is circulating in the blood stream and may therefore be expressed basically everywhere in the body. Further, studies with prophylactic treatment of patients with a severe form of the disease have demonstrated that a minimal elevation of circulating coagulation factor above 1% can already improve the clinical outcome and avoid the majority of lesions caused by the disease, i.e. joint destruction.
  • Several gene therapy approaches have been developed, but testing is still in the early clinical stages. The most promising approaches are currently for the treatment of hemophilia B with adeno-associated viral vectors (AAV).
  • AAV adeno-associated viral vectors
  • Intramuscular injection AAV to skeletal muscle of humans with hemophilia B is safe, but higher doses are required to achieve therapeutic factor IX levels.
  • dose escalation is not possible in this approach, since the risk of the formation of inhibitory antibodies depends on the amount of F.IX antigen expressed in the muscle per injection site.
  • Estimation in a hemophilia B dog model let to the conclusion, that more then 400 intramuscular injections would be necessary to obtain F.IX expression levels of around 1% in humans (Arruda et al ., 2004). This procedure, therefore, is not applicable to humans.
  • F.IX-R338A generated a protein with 2- or 6-fold higher specific activity than F.IX-WT following vector delivery to skeletal muscle or liver, respectively.
  • F.IX-WT and variant forms provide effective hemostasis in vivo upon challenge by tail-clipping assay.
  • intramuscular injection of AAV-F.IX variants did not trigger antibody formation to F.IX in mice tolerant to F.IX-WT.
  • R338A variant first described by Chang et al. (1998), another variant, V86A, with higher specific F.IX activity has been described ( Chang et al. 2002).
  • the present invention aims to improve the methods and means for the treatment and/or prophylaxis of bleeding disorders as present in the prior art and it is, thus, an objective of the present invention to provide improved methods and means which allow for an effective, specific and targeted treatment and/or prophylaxis of bleeding disorders, in particular hemophilia A and/or B.
  • this object is solved by providing a variant of a vitamin K-dependent serine protease of the coagulation cascade wherein the variant is characterized in that it has clotting activity in absence of its cofactor.
  • the coagulation factors VII (F.VII), IX (F.IX) and X (F.X) as well as the cofactor inhibitor protein C (which degrades the co-factors F.Va and F.VIIIa) and thrombin are vitamin K-dependent serine proteases of the coagulation cascade.
  • Vitamin K is an essential factor to a hepatic gamma-glutamyl carboxylase that adds a carboxyl group to glutamic acid residues (in the Gla-domain) on factors II (thrombin), VII, IX and X, as well as protein S, protein C and protein Z.
  • serine protease family of clotting factors which includes factor II (F.II), factor VII (F.VIII), factor IX (F.IX), factor X (F.X), and protein C (PC), is defined by a specific domain structure (Furie and Furie, 1988).
  • Serine proteases are characterised by the presence of a serine residue in the active site of the enzyme. The mentioned proteins circulate in a zymogene form and are activated by cleavage of an activation site. There is great homology between all vitamin K-dependent coagulation proteases. Several of them exhibit the increase in activity only assembled in a complex consisting of the protease, cofactors and phosphlipid membranes.
  • a variant of a vitamin K-dependent serine protease of the coagulation cascade is preferably selected from a variant of factor VII (F.VII), factor IX (F.IX), factor X (F.X), protein C or thrombin.
  • variants preferably refers to amino acid substitution, addition (insertion) or deletion variants or derivatives of the naturally occurring protein.
  • Variants comprise furthermore an amino acid sequence comprising modified amino acid(s), unnatural amino acid(s) or peptidomimetic(s) or further compounds which can mimic a peptide backbone/structure.
  • Variants can also comprise the substitution or coupling with parts of other molecules or coupling with other molecules.
  • Amino acid substitutions comprise conservative as well as non conservative replacement by other amino acids or by isosteres (modified amino acids that bear close structural and spatial similarity to protein amino acids), amino acid additions or isostere additions.
  • a variant of the vitamin K-dependent serine protease factor IX (F.IX) or activated factor XI (F.IXa) is provided, wherein the variant of F.IX is characterized in that it has clotting activity in absence of its cofactor, wherein the cofactor is factor VIII (F.VIII) or activated factor VIII (F.VIIIa).
  • F.IX Factor IX
  • F.IX Factor IX
  • the amino acid sequence of SEQ ID NO. 2 contains the signal peptide and the pro-peptide of F.IX. The actual numbering starts at -46(Met); +1 is Tyr.
  • Activated factor IX within this patent application refers to the activated F.IX molecule through cleavage of the 35 amino acid activation peptide as described above.
  • the F.IX numbering system is used (according to Kurachi and Davie, 1982, except when indicated otherwise.
  • the chymotrypsinogen numbering is used for the description of certain amino acids in homology to the serine protease chymotrypsin.
  • the chymotrypsin numbering is only used when explicitly indicated herein.
  • the "clotting activity” or "functional activity” of F.IX can also be referred to as specific F.IX activity, which is usually measured in Unit/milligram (U/mg). Since one Unit (1 U) of F.IX is referred to as the amount of F.IX in 1 millilitre (ml) of normal human plasma, which corresponds to 5000 ng F.IX, the usual specific activity is around 200 U/mg. Since the specific activity of F.IX is defined as protease activity in the plasma in presence of F.VIII, there is no definition in use in the art for (clotting) activity in absence of cofactor F.VIII. Therefore, the clotting activity in absence of F.VIII, also called “F.VIII-like activity", is expressed herein as percentage of the activity, which an equal amount of wild type F.IX would exhibit in the presence of F.VIII.
  • a F.IX variant has "clotting activity" in absence of its cofactor, when it corrects the blood coagulation deficiency caused by the absence of clotting F.VIII in the blood, which in case of a disease can either be due to absence of the F.VIII protein, presence of a defective F.VIII protein, or inhibition of the F.VIII protein, for example by inhibitory antibodies.
  • the assay system used in the present invention for determining "clotting activity” or “functional activity” of the variants of a vitamin K-dependent serine protease of the coagulation cascade, preferably of F.IX variants, is an one stage assay based on the aPTT.
  • the activated partial thromboplastin time (aPTT or APTT) is a performance indicator measuring the efficacy of both the "intrinsic” (now referred to as the contact activation pathway ) and the common coagulation pathways. Apart from detecting abnormalities in blood clotting, it is also used to monitor the treatment effects with heparin, a major anticoagulant.
  • F.VIII or F.IX activity levels in a sample For the determination of the F.VIII or F.IX activity levels in a sample, the test is performed by spiking the sample into F.VIII or F.IX deficient plasma for measurement of the F.VIII or F.IX activity, respectively. This test is referred to as F.VIII or F.IX one stage assay. Now, F.VIII independent activity of a F.IX variant can be determined by one stage assay and using F.VIII deficient plasma.
  • blood is collected with oxalate or citrate which arrest coagulation by binding calcium.
  • the plasma is separated from the corpuscular parts of the blood by centrifugation.
  • the protein is diluted in imidazole buffer.
  • the sample is mixed and added to standardized factor (VIII or IX) deficient plama.
  • VIII or IX standardized factor
  • phospholipid, an activator (such as silica, celite, kaolin, ellagic acid), and calcium to reverse the anticoagulant effect of the oxalate) are mixed into the plasma sample.
  • the time is measured until a thrombus (clot) forms.
  • the test is termed "partial" due to the absence of tissue factor from the reaction mixture (see Langdell et al ., 1953).
  • the variants of faxtor IX according to the invention have clinical relevant clotting activity (or clotting activity with clinical relevance), i.e. clotting activity which makes the variants suitable for clinical applications, as disclosed herein below.
  • a preferred clotting activity with clinical relevance is 1% or more clotting activity of the variant in absence of cofactor F.VIII, wherein 100% refers to the activity of wild type F.IX in presence of cofactor F.VIII or F.VIIIa.
  • 100% refers to the activity of wild type F.IX in presence of cofactor F.VIII or F.VIIIa.
  • Around 1% sustained factor VIII or factor IX levels are enough in prophylactic treatment regimens to prevent major bleeding complications in severe hemophilia patients.
  • F.IX variant levels of 100% of normal (around 5000 ng/ml) additional to the already physiologically present F.IX would be necessary.
  • Such a treatment seems feasible and therefore the clinically relevant "factor VIII-like" activity is estimated at 1%.
  • the variant factor IX of the invention comprises a modification of the 99-loop, preferably by amino acid substitutions, insertions and/or deletions.
  • a modification of the 99-loop can also be achieved by affecting the loop structure by amino acid substitutions, insertions and/or deletions of adjacent amino acid residues or residues interacting otherwise with the 99-loop.
  • the 99-loop or insertion loop 80-90 (according to chymotrypsinogen numbering) of factor IX encompasses amino acid residues 256 to 268 (F.IX numbering).
  • the 99-loop is positioned near the active site and plays a role in the activation of F.IX. According to Sichler et al. (2003), Tyr-177 locks the 99-loop in an inactive conformation which, in the physiologic complex, is released by cofactor F.VIIIa. F.X is then able to rearrange the unlocked 99-loop and subsequently binds to the active site cleft.
  • the variant factor IX comprises preferably at least one amino acid substitution in a position selected from the group of 265, 4, 338, 377, 259, 345, 1, 10, 37, 50, 85, 116, 119, 120, 181, 217, 235, 245, 253, 259, 301, 360, 383, 340, 86, 25, 34, 290, 291, 274, 353, 358, 375, 388, 35.
  • the variant factor IX according to the invention comprises at least one amino acid substitution in a position selected from the group of 255 to 269, 383, 181, 290, 388, 34, 25, 353, 358, 338, 377, 4, 86, 217, and/or a modification of the 99-loop.
  • the variant factor IX comprises at least an amino acid substitution selected from K265T, I383V, V181I, I290L, E388G, N34D, F25Y, F353Y, R358A, R338A, S377W, G4Y, V86A, V217L and/or a modification of the 99-loop.
  • the variant factor IX comprises the amino acid substitution K265T (K98T according to chymotrypsinogen numbering) and a further amino acid substitution.
  • the further amino acid substitution is preferably an (more preferably at least one) amino acid substitution in a position selected from the group of 4, 338, 377, 259, 345, 1, 10, 37, 50, 85, 116, 119, 120, 181, 217, 235, 245, 253, 259, 301, 360, 383, 340, 86, 25, 34, 290, 291, 274, 353, 358, 375, 388 and/or 35, more preferably selected from the group of: 383, 181, 290, 388, 34, 25, 353, 358, 338, 377, 4, 86 and/or 217.
  • the variant factor IX comprises the amino acid substitution K265T and an amino acid substitution selected from I383V, V181I, I290L, E388G, N34D, F25Y, F353Y, R358A, R338A, S377W, G4Y, V86A and/or V217L.
  • the variant factor IX comprises multiple amino acid substitutions from the group of amino acid positions 265, 4, 338, 377, 259, 345, 1, 10, 37, 50, 85, 116, 119, 120, 181, 217, 235, 245, 253, 259, 301, 360, 383, 340, 86, 25, 34, 290, 291, 274, 353, 358, 375, 388, 35, wherein "multiple amino acid substitutions" refers to substitutions in 2, 3, 4 or more positions.
  • F.IX variant which allows F.VIII-independent therapy of bleeding disorders: a variant with an amino acid substitution in position 265, preferably K265T (K98T according to chymotrypsin numbering).
  • K265T has been described in a different context in Sichler et al. 2003. Kolkman and Mertens (2000) describe a K265A variant.
  • F.IXa has a poor activity compared to other serine proteases like F.Xa.
  • exchanging only few amino acids affecting the 99-loop of F.IX by corresponding F.X sequences resulted in a dramatic improvement of amidolytic activity (up to several thousand-fold) in kinetic studies with truncated recombinant F.IXa variants using peptide substrates (see Hopfner et al ., 1997 and Sichler et al., 2003)).
  • a shift in specificity towards a "F.X-like" function was observed.
  • the variant factor IX is characterized that it has clotting activity in absence of cofactor F.VIII and has the K265T amino acid substitution.
  • F.IX protein activity of F.IX can be even further modified by introduction of additional amino acid substitution to the amino acid substitution of Group A in order to obtain a F.IX variant with desired properties: Amino acid position Amino acid substitution Group A 265 K265T Group B 383, 181, 290 I383V, V181I, I290L Group C 388, 34, 25, 353, 358, 383 E388G, N34D, F25Y, F353Y, R358A, I383V Group D 338,377,4,86,217 R338A, S377W, G4Y, V86A, V217L
  • the inventors further added two additional amino acid substitutions (Group B ), resulting in a protein (V181I/K265T/I383V) with 167% F.IX and 16% "F.VIII like” activity.
  • the variant accordingly has a 160,000-fold higher clotting activity in absence of F.VIII compared to the wild type protein.
  • These additional amino acid substitutions were chosen in a way to maximally increase F.VIII independent F.IX activity without exorbitantly increasing the F.IX specific activity.
  • All variants of Group A and in combination of Group A are especially suitable for the therapy of patients with hemophilia A, inhibitory antibodies and other bleeding disorders as well as for the treatment of hemophilia B.
  • a variant factor IX is characterized in that it has clotting activity in absence of cofactor F.VIII, and comprises at least one amino acid substitution in a position selected from the group of 265, 383, 181 and 290.
  • the variant factor IX comprises the amino acid substitution K265T and amino acid substitution(s) in a position selected from the group of 383, 181 and/or 290 (group B), more preferably comprises the amino acid substitution K265T and amino acid substitution(s) selected from I383V, V181I and/or I290L.
  • F.IX variants of Group A + B have a F.VIII-independent clotting activity which is increased compared to the respective clotting activity of the basis variant ( Group A ).
  • a variant factor IX is characterized in that it has clotting activity in absence of cofactor F.VIII, but decreased activity in presence of cofactor F.VIII, and comprises at least one amino acid substitution in a position selected from the group of 265, 383, 388, 34, 25, 353 and/or 358.
  • the variant factor IX comprises the amino acid substitution K265T and amino acid substitution(s) in a position selected from the group of 388, 34, 25, 383, 353 and/or 358 ( Group C ), more preferably comprises the amino acid substitution K265T and amino acid substitution(s) selected from E388G, N34D, F25Y, F353Y, I383V and/or R358A.
  • F.IX variants of Group A + C have a F.VIII-dependent activity which is decreased compared to wild type and preferably to the respective activity of the basis variant ( Group A ) (or preferably decreased compared to variant(s) of Group A + B ).
  • these F.IX variants of Group A + C restrict F.VIII-dependent activity and minimize possible thrombogenic risks.
  • a variant factor IX is characterized in that it has clotting activity in absence of cofactor F.VIII, but decreased activity in presence of cofactor F.VIII and comprises at least one amino acid substitution in a position selected from the group of 265, 383, 181, 290, 388, 34, 25, 353 and/or 358,
  • the variant factor IX comprises the amino acid substitution K265T and amino acid substitution(s) in a position selected from the group of 383, 181, 290, 388, 34, 25, 353 and/or 358 (group B + C), more preferably comprises the amino acid substitution K265T and amino acid substitution(s) selected from I383V, V181I, I290L, E388G, N34D, F25Y, F353Y and/or R358A.
  • a variant of factor IX is characterized in that it has increased clotting activity in presence of its cofactor compared to wild type, wherein the cofactor is factor VIII (F.VIII) or activated factor VIII (F.VIIIa).
  • a variant factor IX according to this aspect of the present invention comprises at least one amino acid substitution in a position selected from the group of 338, 377, 4, 86 and/or 217, more preferably comprises at least one amino acid substitution selected from R338A, S377W, G4Y, V86A and/or V217L.
  • the variants of Group D and variants that are combined with Group D are especially suitable for the treatment of hemophilia B.
  • a protein with isolated high F.IX activity in presence of F.VIII is a good therapeutic for the treatment of F.IX deficiency.
  • the amino acid subsitutions of Group D also increase F.IX activity in presence of F.VIII in absence of the above mentioned K265T mutation (Group A).
  • Table 2 A list of variants tested for this purpose without introduction of the K265T mutation are shown in Table 2.
  • a variant factor IX is characterized in that it has clotting activity in absence of cofactor F.VIII and increased clotting activity in presence of cofactor F.VIII compared to wildtype, and comprises at least one amino acid substitution in a position selected from the group of 265, 338, 377, 4, 86 and/or 217.
  • the variant factor IX comprises the amino acid substitution K265T and amino acid substitution(s) in a position selected from the group of 338, 377, 4, 86 and/or 217 (group D), more preferably comprises the amino acid substitution K265T and amino acid substitution(s) selected from R338A, S377W, G4Y, V86A and/or V217L.
  • F.IX variants of Group A + D have a F.VIII-dependent clotting activity which is increased compared to the respective F.VIII-dependent clotting activity of wild type, and preferably of the basis variant ( Group A ). They have also an increased potency for treatment of hemophilia B.
  • a variant factor IX is characterized in that it has (increased) clotting activity in absence of cofactor F.VIII and increased clotting activity in presence of cofactor F.VIII, and comprises at least one amino acid substitution in a position selected from the group of 265, 383, 181, 290, 338, 377, 4, 86 and/or 217.
  • the variant factor IX comprises the amino acid substitution K265T and amino acid substitution(s) in a position selected from the group of 383, 181, 290, 338, 377, 4, 86 and/or 217, more preferably comprises the amino acid substitution K265T and amino acid substitution(s) selected from I383V, V181I, I290L, R338A, S377W, G4Y, V86A and/or V217L.
  • the variant factor IX according to the invention is more preferably selected from
  • the variants of factor IX according to the invention comprise a further compound or moiety, which is preferably covalently attached to the variant (conjugate).
  • the further compound or moiety is selected from
  • the above object is furthermore solved by providing nucleic acids encoding the variant factor IX according to the present invention.
  • nucleic acid refers to DNA, RNA and derivatives thereof, DNA and/or RNA comprising modified nucleotides/nucleosides.
  • the nucleic acid is operably linked to a promoter and/or terminator sequence.
  • Preferred promoter and/or terminator sequences are the human alpha1 anti-trypsin promoter, the hepatic locus control region 1, or the cytomegalovirus promoter and a polyadenylation signal vom human or bovine growth hormone of the Simianese Virus 40.
  • the skilled artisan is able to select suitable promoter and/or terminator sequences.
  • a nucleic acid is "operably linked" to a promoter and/or terminator sequence when the transcription/translation of the nucleic acid is controlled by the respective promoter/terminator, preferably in a cell and by the cellular transcription/translation machinery, such that e.g. the encoded protein can be obtained from the nucleic acid.
  • the nucleic acid is an expression plasmid, a gene therapy construct, a sequence encoded in a gene transfer vector, a gene sequence used for DNA modification or repair, or similar.
  • Preferred gene therapy constructs are viral and non-viral vectors, such as adeno-associated viral vectors (AAV), plasmid vectors, or minicircle vectors, as described e.g. in (Schuettrumpf et al ., 2005).
  • AAV adeno-associated viral vectors
  • plasmid vectors plasmid vectors
  • minicircle vectors as described e.g. in (Schuettrumpf et al ., 2005).
  • the object is furthermore solved by providing a pharmaceutical composition comprising at least one variant of factor IX (F.IX) of the invention or at least one nucleic acid of the invention, and optionally pharmaceutically acceptable carrier(s) and/or excipient(s).
  • a pharmaceutical composition comprising at least one variant of factor IX (F.IX) of the invention or at least one nucleic acid of the invention, and optionally pharmaceutically acceptable carrier(s) and/or excipient(s).
  • Suitable pharmaceutically acceptable carrier(s) and/or excipient(s) are known in the art. The skilled artisan will selected the preferred pharmaceutically acceptable carrier(s) and/or excipient(s) depending on the intended application of the pharmaceutical composition, such as disorder to be treated, patient to be treated, treatment regimen etc.
  • the object is furthermore solved by providing the variants of a vitamin K-dependent serine protease of the coagulation cascade, most preferably the variants of factor IX, as disclosed in the present invention or the nucleic acids encoding them or the pharmaceutical compositions of the invention for the diagnosis, prevention and/or treatment of diseases.
  • the disease to be diagnosed, prevented and or treated is preferably a bleeding disorder or bleeding.
  • a "bleeding disorder” is preferably hemophilia A and/or hemophilia B, hemophilia caused or complicated by inhibitory antibodies to factor VIII, by a deficiency of factor VIII or factor IX, or by the presence of a non functional factor VIII or factor IX protein, or any other bleeding or bleeding tendency.
  • the bleeding disorder is hemophilia A, hemophilia caused or complicated by inhibitory antibodies to factor F.VIII or F.VIIIa, hemophilia B.
  • the bleeding disorder or bleeding is a bleeding disorder where by-passing agents are used, including e.g. neonatal coagulopathies; severe hepatic disease; high-risk surgical procedures; traumatic blood loss; bone marrow transplantation; thrombocytopenias and platelet function disorders; urgent reversal of oral anticoagulation; congenital deficiencies of factors V, VII, X, and XI; and von Willebrand disease with inhibitors to von Willebrand factor, blood loss in connection with large injuries, cerebral bleedings, thrombocyte function disorders.
  • by-passing agents including e.g. neonatal coagulopathies; severe hepatic disease; high-risk surgical procedures; traumatic blood loss; bone marrow transplantation; thrombocytopenias and platelet function disorders; urgent reversal of oral anticoagulation; congenital deficiencies of factors V, VII, X, and XI; and von Willebrand disease with inhibitors to von Willebrand factor, blood loss in connection with large injuries, cerebral bleedings, thro
  • the object is furthermore solved by using a variant of a vitamin K-dependent serine protease of the coagulation cascade, most preferably the variants of factor IX, as disclosed in the present invention or the nucleic acids encoding them for the manufacture of a medicament for the treatment and/or the prevention of a bleeding disorder or bleeding.
  • the variant of factor IX (F.IX), the nucleic acid or the pharmaceutical composition of the invention are used for protein infusion therapy, cellular therapy, gene therapy and/or prophylaxis of a bleeding disorder or bleeding.
  • Diagnosis, prevention and/or treatment, wherein the disease is hemophilia A or hemophilia caused or complicated by inhibitory antibodies to factor F.VIII or F.VIIIa:
  • the inventors are the first to apply a variant of Group A, in particular K265T, for the treatment of hemophilia A or hemophilia caused or complicated by inhibitory antibodies to factor F.VIII or F.VIIIa.
  • the variant F.IX molecules with higher protease/clotting activity in absence of F.VIII could be an alternative to common bypassing agents, with the advantage of being activated directly at the site of injury. This would resemble physiologic clot formation, prevent the infusion of already activated proteases as usual in the available bypassing agents at the moment, and make therapy safer.
  • a zymogene F.IX variant would presumably also have a far longer half life, enabling prophylactic substitution therapy also in inhibitor patients.
  • patients lacking F.VIII could even be suitable for a gene transfer approach using the smaller and less immunogenic F.IX, for which gene therapy studies are far more promising at the moment.
  • the proposed F.IX variants could even bundle the efforts offering therapy for patients with hemophilia A and hemophilia B, or with inhibitory antibodies to F.VIII.
  • the variant would also be useful in the treatment of other bleeding disorders.
  • variants could be used in diagnostic testing systems or for the development and screening for direct F.IXa inhibitory substances, which since a long time are desired as anticoagulants, but for which no effective screening was possible, due to the low efficacy of F.IXa without assembly in the tenase complex.
  • Diagnosis, prevention and/or treatment, wherein the disease is hemophilia B, by all variants described herein preferably by
  • the variants of the present invention are suitable tools to treat patients with bleeding disorder using protein administration, or cell- or gene therapeutic administration (viral, DNA, RNA, or other vectors).
  • Diseases for treatment are hemophilia A and B, also caused or complicated by inhibitory antibodies to FVIII, for treatment of bleeding and for prophylactic therapy.
  • the object is furthermore solved by providing a method for screening of anticoagulant compounds (anticoagulants), preferably substances that directly inhibit F.IXa.
  • Such a method comprises the use of at least one variant factor IX of the present invention, as defined herein.
  • tenase refers to complex of the activated forms of the blood coagulation factors factor VIII (F.VIIIa) and factor IX (F.IXa). It forms on a phospholipid surface in the presence of calcium and is responsible for the activation of factor X).
  • variants are suitable tools in diagnostic testing systems or for the development and screening for direct F.IXa inhibitory substances, which since a long time are desired as anticoagulants, but for which no effective screening was possible, due to the low efficacy of F.IXa without assembly in the tenase complex.
  • a screening method according to the invention is preferably a method for identifying a compound which binds to a variant factor IX of the present invention and/or which modulates its activity, preferably comprising the following steps:
  • the inventors first introduced the mutations Y259F/K265T/Y345T (FTT) into F.IX and expressed the protein in tissue culture. Basically no effect was seen on F.IX specific activity; however the activity in F.VIII-deficient plasma increased dramatically. Since this activity is still a small fraction of the F.IX specific activity (100% of F.IX antigen corresponds to 2 % of "F.VIII-like” activity), the inventors concentrated the variant proteins to concentrations of 20,000 to 40,000 ng/ml (400 -800% of normal plasma concentration). In this concentration "F.VIII-like" activities of up to over 30% could be measured, while no activity was detected for WT F.IX or negative controls.
  • FTT Y259F/K265T/Y345T
  • the inventors combined the FTT variant with several other mutations in order to generate F.IX molecules with different properties.
  • Figure 3 gives an overview of the tested mutations and the activity of the variants in F-VIIL-or F-IX-deficient plasma.
  • the inventors further tested variants and combined them to obtain molecules with high F.IX activity in presence of F.IX.
  • Table 3 shows several variants with more then 10-fold increase in activity. Also apparent from this table is the fact that combining mutations with desired increased activity leads to combined variants with highest activity levels. Some of the variants, like R338A/S377W, were also tested for their activity in absence of F.VIII (Table 1). However, only in combination with the K265T variant an enhanced effect on the F.VIII independent F.IX activity could be observed.
  • the inventors combined single mutations with a desired effect to obtain variants with further increased desired high activities.
  • the K265T variant has 6.6% activity in absence of F.VIII and 191% activity in presence of F.VIII.
  • the inventors combined the K265T mutation with either mutation I383V or V181I.
  • the resulting variants V181I/K265T and K265T/I383V had 9.0% and 8.7% activity in absence of F.VIII, and 219% and 139% activity in presence of F.VIII.
  • This moderate increase in activity in absence of F.VIII could further be significantly improved by combining all three mutations to the variant V181I/K265T/I383V without increasing the activity in presence of F.VIII to 16,4% and 209%, respectively.
  • Table 1 Clotting activities of factor IX variants in absence and presence of F.VIII. Values are shown in percent, being 100% the activity of wild type factor IX in normal human pool plasma with normal human levels of both F.IX and F.VIII. Standard error of mean (S.E.M.) Variants Activity (%) without F.VIII S.E.M. Activity (%) with F.VIII S.E.M.
  • Proteins show altered factor IX specific activity (in percent compared to wild type F.IX). F.IX activity in absence of F.VIII is below detection limits by one-stage assay method. Standard error of mean (S.E.M.) Variants F.IX Activity (%) S.E.M.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
EP08013561A 2008-07-28 2008-07-28 Variantes du facteur IX dotées d'activité de coagulation en l'absence de leur cofacteur et leur utilisation pour le traitement de troubles du sang Withdrawn EP2149603A1 (fr)

Priority Applications (19)

Application Number Priority Date Filing Date Title
EP08013561A EP2149603A1 (fr) 2008-07-28 2008-07-28 Variantes du facteur IX dotées d'activité de coagulation en l'absence de leur cofacteur et leur utilisation pour le traitement de troubles du sang
EP11005215.6A EP2390323B1 (fr) 2008-07-28 2009-07-28 Variantes du facteur IX dotées d´activité de coagulation en l´absence de leur cofacteur et leur utilisation pour le traitement de troubles du sang
JP2011520375A JP6029826B2 (ja) 2008-07-28 2009-07-28 補因子の非存在下において凝固活性を有する第ｉｘ因子変異体および出血性疾患の処置のためのその使用
KR1020117001765A KR101768896B1 (ko) 2008-07-28 2009-07-28 그의 보조인자의 부존재하에서 응고활성을 갖는 인자 ｉｘ 변이체 및 출혈 질환을 치료하기 위한 그의 용도
ES17164245T ES2753638T3 (es) 2008-07-28 2009-07-28 Variantes del Factor IX con actividad coagulante en presencia de su cofactor y su uso para el tratamiento de alteraciones hemorrágicas
EP19191719.4A EP3623470A3 (fr) 2008-07-28 2009-07-28 Variantes du facteur ix dotées d'activité de coagulation en l'absence de leur cofacteur et leur utilisation pour le traitement de troubles du sang
CA3033578A CA3033578C (fr) 2008-07-28 2009-07-28 Variants du facteur ix presentant une activite coagulante en l'absence de leur cofacteur et leur utilisation dans le cadre du traitement de troubles hemorragiques
PCT/EP2009/005465 WO2010012451A1 (fr) 2008-07-28 2009-07-28 Variants du facteur ix présentant une activité coagulante en l'absence de leur cofacteur et leur utilisation dans le cadre du traitement de troubles hémorragiques
EP17164245.7A EP3241899B1 (fr) 2008-07-28 2009-07-28 Variantes du facteur ix dotées d'activité de coagulation en la présence de leur cofacteur et leur utilisation pour le traitement de troubles du sang
KR1020177022245A KR101947424B1 (ko) 2008-07-28 2009-07-28 그의 보조인자의 부존재하에서 응고활성을 갖는 인자 ｉｘ 변이체 및 출혈 질환을 치료하기 위한 그의 용도
ES11005215.6T ES2441167T3 (es) 2008-07-28 2009-07-28 Variantes del Factor IX con actividad coagulante en ausencia de su cofactor y su uso para el tratamiento de alteraciones hemorrágicas
AU2009275391A AU2009275391B2 (en) 2008-07-28 2009-07-28 Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
US13/001,187 US10125357B2 (en) 2008-07-28 2009-07-28 Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
EP09777493A EP2318526A1 (fr) 2008-07-28 2009-07-28 Variants du facteur ix présentant une activité coagulante en l'absence de leur cofacteur et leur utilisation dans le cadre du traitement de troubles hémorragiques
CN2009801296698A CN102112608B (zh) 2008-07-28 2009-07-28 在不存在其辅因子的情况下具有凝血活性的因子ix变体及其治疗出血障碍的用途
ES14165396.4T ES2628688T3 (es) 2008-07-28 2009-07-28 Variantes del Factor IX con actividad coagulante en ausencia de su cofactor y su uso para el tratamiento de alteraciones hemorrágicas
EP14165396.4A EP2767587B1 (fr) 2008-07-28 2009-07-28 Variantes du facteur IX dotées d'activité de coagulation en l'absence de leur cofacteur et leur utilisation pour le traitement de troubles du sang
CA2729501A CA2729501C (fr) 2008-07-28 2009-07-28 Variants du facteur ix presentant une activite coagulante en l'absence de leur cofacteur et leur utilisation dans le cadre du traitement de troubles hemorragiques
US16/148,819 US10883097B2 (en) 2008-07-28 2018-10-01 Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08013561A EP2149603A1 (fr) 2008-07-28 2008-07-28 Variantes du facteur IX dotées d'activité de coagulation en l'absence de leur cofacteur et leur utilisation pour le traitement de troubles du sang

Publications (1)

Publication Number Publication Date
EP2149603A1 true EP2149603A1 (fr) 2010-02-03

Family

ID=40032573

Family Applications (6)

Application Number Title Priority Date Filing Date
EP08013561A Withdrawn EP2149603A1 (fr) 2008-07-28 2008-07-28 Variantes du facteur IX dotées d'activité de coagulation en l'absence de leur cofacteur et leur utilisation pour le traitement de troubles du sang
EP14165396.4A Active EP2767587B1 (fr) 2008-07-28 2009-07-28 Variantes du facteur IX dotées d'activité de coagulation en l'absence de leur cofacteur et leur utilisation pour le traitement de troubles du sang
EP09777493A Ceased EP2318526A1 (fr) 2008-07-28 2009-07-28 Variants du facteur ix présentant une activité coagulante en l'absence de leur cofacteur et leur utilisation dans le cadre du traitement de troubles hémorragiques
EP17164245.7A Active EP3241899B1 (fr) 2008-07-28 2009-07-28 Variantes du facteur ix dotées d'activité de coagulation en la présence de leur cofacteur et leur utilisation pour le traitement de troubles du sang
EP19191719.4A Withdrawn EP3623470A3 (fr) 2008-07-28 2009-07-28 Variantes du facteur ix dotées d'activité de coagulation en l'absence de leur cofacteur et leur utilisation pour le traitement de troubles du sang
EP11005215.6A Active EP2390323B1 (fr) 2008-07-28 2009-07-28 Variantes du facteur IX dotées d´activité de coagulation en l´absence de leur cofacteur et leur utilisation pour le traitement de troubles du sang

Family Applications After (5)

Application Number Title Priority Date Filing Date
EP14165396.4A Active EP2767587B1 (fr) 2008-07-28 2009-07-28 Variantes du facteur IX dotées d'activité de coagulation en l'absence de leur cofacteur et leur utilisation pour le traitement de troubles du sang
EP09777493A Ceased EP2318526A1 (fr) 2008-07-28 2009-07-28 Variants du facteur ix présentant une activité coagulante en l'absence de leur cofacteur et leur utilisation dans le cadre du traitement de troubles hémorragiques
EP17164245.7A Active EP3241899B1 (fr) 2008-07-28 2009-07-28 Variantes du facteur ix dotées d'activité de coagulation en la présence de leur cofacteur et leur utilisation pour le traitement de troubles du sang
EP19191719.4A Withdrawn EP3623470A3 (fr) 2008-07-28 2009-07-28 Variantes du facteur ix dotées d'activité de coagulation en l'absence de leur cofacteur et leur utilisation pour le traitement de troubles du sang
EP11005215.6A Active EP2390323B1 (fr) 2008-07-28 2009-07-28 Variantes du facteur IX dotées d´activité de coagulation en l´absence de leur cofacteur et leur utilisation pour le traitement de troubles du sang

Country Status (9)

Country Link
US (2) US10125357B2 (fr)
EP (6) EP2149603A1 (fr)
JP (1) JP6029826B2 (fr)
KR (2) KR101947424B1 (fr)
CN (1) CN102112608B (fr)
AU (1) AU2009275391B2 (fr)
CA (2) CA2729501C (fr)
ES (3) ES2441167T3 (fr)
WO (1) WO2010012451A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014070349A1 (fr) * 2012-10-29 2014-05-08 Regents Of The University Of Minnesota Variants du facteur ix
WO2020089619A1 (fr) * 2018-10-31 2020-05-07 Ucl Business Ltd Polypeptides modifiés du facteur ix
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
US12209262B2 (en) 2018-08-20 2025-01-28 Ucl Business Ltd Factor IX encoding nucleotides

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3581650T3 (da) 2008-09-15 2023-03-13 Uniqure Biopharma B V Faktor ix polypeptidmutant, anvendelse deraf og en fremgangsmåde til fremstilling deraf
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
EP2680875B1 (fr) 2011-03-02 2019-10-23 Novo Nordisk Health Care AG Facteur de coagulation ciblant tlt-1 sur des plaquettes activées
EP2737311B1 (fr) 2011-07-25 2020-12-02 Bioverativ Therapeutics Inc. Dosages pour la surveillance de troubles hémostatiques
CN103173482A (zh) * 2011-12-22 2013-06-26 武汉科技大学 野生型和突变体hFⅨ毕赤酵母表达载体及构建方法和应用
EP2666782A1 (fr) * 2012-05-22 2013-11-27 Imnate Sarl Facteur VIII de coagulation avec immunogénicité réduite
CN103060366A (zh) * 2012-12-25 2013-04-24 武汉科技大学 人凝血因子ⅸ突变体毕赤酵母表达载体及构建方法和应用
HUE053136T2 (hu) 2013-02-15 2021-06-28 Bioverativ Therapeutics Inc Optimizált VIII. faktor gén
ES2680932T3 (es) * 2013-05-14 2018-09-11 Struszym, S.L. Métodos de determinación de actividades de los factores de coagulación
EP2881463A1 (fr) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Variants du facteur IX présentant une activité de coagulation en l'absence de leur cofacteur et/ou à une activité de coagulation F.IX accrue et leur utilisation pour traiter des troubles de saignement
WO2016004113A1 (fr) * 2014-06-30 2016-01-07 Biogen Ma Inc. Gène du facteur ix optimisé
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
EP3325010B1 (fr) 2015-07-23 2023-06-21 The Regents of The University of California Anticorps anti-facteur de coagulation xia et leurs utilisations
PL3411478T3 (pl) 2016-02-01 2022-10-03 Bioverativ Therapeutics Inc. Geny zoptymalizowanego czynnika VIII
JP2020526203A (ja) 2017-07-10 2020-08-31 ユニキュアー アイピー ビー．ブイ． ヒトにおけるａａｖ遺伝子療法のための手段及び方法
WO2020104480A1 (fr) * 2018-11-19 2020-05-28 Uniqure Biopharma B.V. Vecteurs à base de virus adéno-associé pour l'expression de fviii mimétiques, et utilisations correspondantes
CN113573726A (zh) * 2019-03-19 2021-10-29 康诺贝林伦瑙有限公司 因子ix变体及其在治疗中的用途
CN110684798A (zh) * 2019-09-03 2020-01-14 深圳新诺微环生物科技有限公司 肌肉靶向的微环dna基因治疗
CA3183557A1 (fr) 2020-06-24 2021-12-30 Bioverativ Therapeutics Inc. Procedes pour retirer le facteur viii a l'etat libre contenu dans des preparations de vecteurs lentiviraux modifies pour exprimer ladite proteine
CN114277057B (zh) * 2021-07-09 2023-10-13 上海天泽云泰生物医药有限公司 用于治疗或预防b型血友病的重组腺相关病毒载体和方法
AU2022379633A1 (en) 2021-10-27 2024-04-11 Regeneron Pharmaceuticals, Inc. Compositions and methods for expressing factor ix for hemophilia b therapy

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003496A1 (fr) * 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Facteur ix antihemophilique presentant une activite de coagulation augmentee
WO2001068109A1 (fr) 2000-03-10 2001-09-20 Emory University Facteur viii modifie
WO2002040544A2 (fr) 2000-11-14 2002-05-23 Board Of Regents, University Of Texas Systems Facteur ix humain mutant a resistance accrue a l'inhibition par l'heparine
EP1282438B1 (fr) 2000-05-10 2005-08-03 Novo Nordisk Health Care AG Utiliasation d'une composition pharmaceutique comprenant un facteur viia et un facteur xiii
WO2007149406A2 (fr) * 2006-06-19 2007-12-27 Nautilus Technology Llc Polypeptides facteurs ix de la coagulation modifiés et leur utilisation thérapeutique
US20080167219A1 (en) * 2007-01-09 2008-07-10 Shu-Wha Lin Recombinant human factor ix and use thereof
WO2008092644A2 (fr) * 2007-02-01 2008-08-07 Baxter International Inc. Protéines mutantes de fix fviii-indépendantes destinées au traitement de l'hémophilie a
WO2008092643A2 (fr) * 2007-02-01 2008-08-07 Baxter International Inc. Protéines mutantes de fix améliorées destinées à traiter l'hémophilie b

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0113854A (pt) * 2000-09-13 2004-07-06 Novo Nordisk As Polipeptìdeo do fator vii, construção de ácido nucleìco, célula hospedeira recombinante animal transgênico, planta transgênica, método para produzir o polipeptìdeo do fator vii, composição farmacêutica, uso de um polipeptìdeo do fator vii, e, métodos para o tratamento de episódios de sangramento e para tratamento ou profilaxia de distúrbios de sangramento em um indivìduo ou para a intensificação do sistema hemostático normal
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
PL1781782T3 (pl) * 2004-08-17 2010-10-29 Csl Behring Gmbh Zmodyfikowane polipeptydy zależne od witaminy K
DE102008034724A1 (de) * 2008-07-25 2010-01-28 Alexander Koslow Verkugelungs- / Zerkleinerungsmaschine

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003496A1 (fr) * 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Facteur ix antihemophilique presentant une activite de coagulation augmentee
WO2001068109A1 (fr) 2000-03-10 2001-09-20 Emory University Facteur viii modifie
EP1282438B1 (fr) 2000-05-10 2005-08-03 Novo Nordisk Health Care AG Utiliasation d'une composition pharmaceutique comprenant un facteur viia et un facteur xiii
EP1282439B1 (fr) 2000-05-10 2005-11-30 Novo Nordisk Health Care AG COMPOSITION PHARMACEUTIQUE COMPRENANT UN FACTEUR VIIa ET UN INHIBITEUR DE TFPI
WO2002040544A2 (fr) 2000-11-14 2002-05-23 Board Of Regents, University Of Texas Systems Facteur ix humain mutant a resistance accrue a l'inhibition par l'heparine
WO2007149406A2 (fr) * 2006-06-19 2007-12-27 Nautilus Technology Llc Polypeptides facteurs ix de la coagulation modifiés et leur utilisation thérapeutique
US20080167219A1 (en) * 2007-01-09 2008-07-10 Shu-Wha Lin Recombinant human factor ix and use thereof
WO2008118507A2 (fr) * 2007-01-09 2008-10-02 Wu, Karl Facteur ix humain recombinant et utilisation de celui-ci
WO2008092644A2 (fr) * 2007-02-01 2008-08-07 Baxter International Inc. Protéines mutantes de fix fviii-indépendantes destinées au traitement de l'hémophilie a
WO2008092643A2 (fr) * 2007-02-01 2008-08-07 Baxter International Inc. Protéines mutantes de fix améliorées destinées à traiter l'hémophilie b

Non-Patent Citations (27)

* Cited by examiner, † Cited by third party
Title
ARRUDA ET AL., BLOOD, vol. 104, 2004, pages 85
CHANG ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 20, 15 May 1998 (1998-05-15), pages 12089 - 12094
CHANG ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 28, 12 July 2002 (2002-07-12), pages 25393 - 25399
CHANG JINLI ET AL: "Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, vol. 273, no. 20, 15 May 1998 (1998-05-15), pages 12089 - 12094, XP002199691, ISSN: 0021-9258 *
CHANG YU-JIA ET AL: "Identification of functionally important residues of the epidermal growth factor-2 domain of factor IX by alanine-scanning mutagenesis. Residues Asn(89)-Gly(93) are critical for binding factor VIIIa", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, vol. 277, no. 28, 12 July 2002 (2002-07-12), pages 25393 - 25399, XP002464800, ISSN: 0021-9258 *
DATABASE CAPLUS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1990, YOSHIOKA, A. ET AL.: "Congenital factor IX abnormailities.", XP002516994 *
DAVIE, E. W.; FUJIKAWA, K.; KISIEL, W., BIOCHEMISTRY, vol. 30, 1991, pages 10363 - 10370
DI SCIPIO RG; KURACHI K; DAVIE EW: "Activation of human factor IX (Christmas factor", J CLIN INVEST, vol. 61, 1978, pages 1528 - 1538
DISCIPIO, R. G. ET AL., BIOCHEMISTRY, vol. 16, 1977, pages 698 - 706
DUFFY EJ; LOLLAR P: "Intrinsic pathway activation of factor X and its activation peptide-deficient derivative, factor Xdes-143-191", J BIOL CHEM, vol. 267, 1992, pages 7821 - 7827, XP001317205
FUJIKAWA, K. ET AL., BIOCHEMISTRY, vol. 13, 1974, pages 4508 - 4516
FURIE B; FURIE BC: "The molecular basis of blood coagulation", CELL, vol. 53, 1988, pages 505 - 518, XP023908863, DOI: doi:10.1016/0092-8674(88)90567-3
GIANNELLI, F. ET AL., NUCLEIC ACIDS RES., vol. 26, 1998, pages 265 - 268
HAMAGUCHI N ET AL: "Mutations in the catalytic domain of factor IX that are related to the subclass hemophilia Bm.", BIOCHEMISTRY 29 JUN 1993, vol. 32, no. 25, 29 June 1993 (1993-06-29), pages 6324 - 6329, XP002516993, ISSN: 0006-2960 *
HARTMANN RUDOLF ET AL: "Variants of recombinant factor IX with enhanced functional properties", BLOOD, vol. 110, no. 11, Part 1, November 2007 (2007-11-01), 49TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 08 -11, 2007, pages 791A, XP009101449, ISSN: 0006-4971 *
HOCKIN MF ET AL., JBIOL CHEM., vol. 277, 2002, pages 18322 - 33
HOPFNER KP ET AL., EMBO J., vol. 16, no. 22, 1997, pages 6626 - 35
KOLKMAN JOOST A ET AL: "Insertion loop 256-268 in coagulation factor IX restricts enzymatic activity in the absence but not in the presence of factor VIII", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, EASTON, PA.; US, vol. 39, no. 25, 27 June 2000 (2000-06-27), pages 7398 - 7405, XP002487244, ISSN: 0006-2960, [retrieved on 20000531] *
KURACHI; DAVIE, PNAS, vol. 79, 1982, pages 6461 - 6464
LANGDELL RD; WAGNER RH; BRINKHOUS KM: "Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure", J LAB. CLIN. MED., vol. 41, no. 4, 1953, pages 637 - 47
LIN SHU-RUNG ET AL: "Identification of Functionally Important Residues in the Protease Domain of Factor IX That Are Critical for Binding Factor XIa, TFPI, and Antibodies", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 100, no. 11, 16 November 2002 (2002-11-16), pages AbstractNo.1006, XP009101499, ISSN: 0006-4971 *
LINDQUIST, P. A.; FUJIKAWA, K.; DAVIE, E. W., J BIOL. CHEM., vol. 253, 1978, pages 1902 - 1909
MANN ET AL., ARTERIOSCLER THROMB VASC BIOL., vol. 23, 2003, pages 17 - 25
MCRAE BJ ET AL.: "Mapping the active sites of bovine thrombin, factor IXa, factor Xa, factor XIa, factor XIIa, plasma kallikrein, and trypsin with amino acid and peptide thioesters: development of new sensitive substrates", BIOCHEMISTRY, vol. 20, 1981, pages 7196 - 7206
SCHUETTRUMPF J ET AL., BLOOD, vol. 105, no. 6, 2005, pages 2316 - 23
SICHLER K ET AL.: "Physiological fIXa activation involves a cooperative conformational rearrangement of the 99-loop", J BIOL CHEM., vol. 278, no. 6, 2003, pages 4121 - 6, XP002487246, DOI: doi:10.1074/jbc.M210722200
SICHLER KATRIN ET AL: "Physiological fIXa activation involves a cooperative conformational rearrangement of the 99-loop", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, vol. 278, no. 6, 7 February 2003 (2003-02-07), pages 4121 - 4126, XP002484064, ISSN: 0021-9258 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014070349A1 (fr) * 2012-10-29 2014-05-08 Regents Of The University Of Minnesota Variants du facteur ix
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
US11517631B2 (en) 2018-08-20 2022-12-06 Ucl Business Ltd Factor IX encoding nucleotides
US12209262B2 (en) 2018-08-20 2025-01-28 Ucl Business Ltd Factor IX encoding nucleotides
WO2020089619A1 (fr) * 2018-10-31 2020-05-07 Ucl Business Ltd Polypeptides modifiés du facteur ix

Also Published As

Publication number Publication date
EP2767587B1 (fr) 2017-04-05
EP3241899A1 (fr) 2017-11-08
EP2390323B1 (fr) 2013-11-27
EP3623470A2 (fr) 2020-03-18
AU2009275391B2 (en) 2015-01-22
US10125357B2 (en) 2018-11-13
US10883097B2 (en) 2021-01-05
CA2729501A1 (fr) 2010-02-04
KR101768896B1 (ko) 2017-08-17
ES2441167T3 (es) 2014-02-03
JP2011528913A (ja) 2011-12-01
EP2390323A2 (fr) 2011-11-30
US20190017039A1 (en) 2019-01-17
CN102112608B (zh) 2013-11-20
EP2767587A2 (fr) 2014-08-20
ES2753638T3 (es) 2020-04-13
KR20110036071A (ko) 2011-04-06
WO2010012451A1 (fr) 2010-02-04
CA3033578A1 (fr) 2010-02-04
EP2390323A3 (fr) 2012-01-11
US20110217284A1 (en) 2011-09-08
EP2767587A3 (fr) 2014-11-26
JP6029826B2 (ja) 2016-11-24
AU2009275391A1 (en) 2010-02-04
EP3241899B1 (fr) 2019-08-21
ES2628688T3 (es) 2017-08-03
CA2729501C (fr) 2019-04-02
CA3033578C (fr) 2022-07-26
EP3623470A3 (fr) 2020-07-22
KR20170096210A (ko) 2017-08-23
KR101947424B1 (ko) 2019-02-13
CN102112608A (zh) 2011-06-29
EP2318526A1 (fr) 2011-05-11

Similar Documents

Publication Publication Date Title
US10883097B2 (en) Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
US11208645B2 (en) Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
US9249404B2 (en) Coagulation factor X polypeptides with modified activation properties
CN101356192A (zh) 用于调节止血的组合物和方法
WO2008119815A1 (fr) Administration sous-cutanée du facteur ix de la coagulation
Spitzer et al. Replacement of isoleucine-397 by threonine in the clotting proteinase factor IXa (Los Angeles and Long Beach variants) affects macromolecular catalysis but not L-tosylarginine methyl ester hydrolysis. Lack of correlation between the ox brain prothrombin time and the mutation site in the variant proteins
FI115635B (fi) Menetelmiä proteiini C:n hajoamisen estämiseksi
US20030186862A1 (en) Factor VIIa compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

AKY No designation fees paid
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100804

REG Reference to a national code

Ref country code: DE

Ref legal event code: 8566